95. A novel comprehensive breakpoint-targeted assay for clinically actionable RNA fusions and aberrant RNAs in solid tumors

Accurate detection of gene fusions is key for supporting cancer diagnosis and therapy selection. Most assays are limited to select intronic DNA breakpoints capture assays or amplicon RNA panels querying only a small number of genes, while whole exome RNA capture or full transcriptome assays lack sensitivity. We developed a pair-ended, strand-specific hybridization-based RNA sequencing assay targeting 1194 unique known fusions pairs and 1104 genes involving 250 fusion genes clinically relevant to most solid tumors.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Fernando Lopez-Diaz, Steven Rivera, Christophe Magnan, Brad Thomas, Yanglong Mou, Segun Jung, Sally Agersborg, Vincent Funari Source Type: research